Literature DB >> 12823907

Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.

Mariëlle E A C Broeders1, Johan Molema, Wim C J Hop, Hans T M Folgering.   

Abstract

Turbuhaler and Salbutamol-Diskus produce therapeutic doses at peak inspiratory flow (PIF) of >30 L/min. However, the optimum flow for Fluticasone-Diskus and Turbuhaler, in terms of total emitted dose and fine particle mass, is >60 L/min. The Turbuhaler achieved a higher output at this flow, as compared to Diskus. For pMDI 25 < PIF < 90 L/min, an actuation time of 0.0-0.2 sec is optimal. The aim of this study was to examine the incidence of optimum inhalation profiles, the effect of instruction, reproducibility, and the relationship between inhalation profiles and patient characteristics in stable asthmatics and mild/moderate/severe COPD patients. For each device, triplicate inhalation profiles were recorded during 6 sessions in a 10-week period. All patients achieved PIF > 30 L/min using Diskus. After instruction, all Diskus inhalations were performed with >60 L/min, except 7% of the inhalations of the severe COPD patients. At least 95% of the Turbuhaler inhalations was also performed with the minimum flow; however, 19% of the inhalations of the severe COPD patients were not optimally performed. The hand-lung coordination was inadequate in 40% of pMDI inhalation profiles, and 80% was performed with a too high flow. The reproducibility of PIF of both dry powder inhalers (DPIs) was very high (coefficient of variation = 4-10%). The reproducibility of the pMDI variables was lower (coefficient of variation = 9-18%). The major lung function variables predictive for PIF(diskus) and PIF(turbuhaler) were maximal inspiratory mouth pressure (MIP), PIF, and inspiratory capacity. No significant predictive lung function variables for PIF(pMDI) were found. Most patients performed reproducible optimum inhalation profiles through Diskus and Turbuhaler. However, in the severe COPD group, 7-19% of the patients were not able to generate the optimum flows through the DPIs. For these patients, a flow-independent aerosol delivery system might be more suitable. The majority of patients were using the pMDI incorrectly. Instruction had no effect. So, we concluded that the pMDI should not be used in these patient groups because of the coordination problems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823907     DOI: 10.1089/089426803321919898

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  18 in total

1.  Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.

Authors:  P Worth Longest; Geng Tian; Ross L Walenga; Michael Hindle
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

2.  Investigation of dry powder inhaler (DPI) resistance and aerosol dispersion timing on emitted aerosol aerodynamic particle sizing by multistage cascade impactor when sampled volume is reduced from compendial value of 4 L.

Authors:  Hlack Mohammed; Jan Arp; Frank Chambers; Mark Copley; Volker Glaab; Mark Hammond; Derek Solomon; Kerry Bradford; Theresa Russell; Yvonne Sizer; Steven C Nichols; Daryl L Roberts; Christopher Shelton; Roland Greguletz; Jolyon P Mitchell
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

3.  Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.

Authors:  Ross L Walenga; P Worth Longest
Journal:  J Pharm Sci       Date:  2016-01-13       Impact factor: 3.534

Review 4.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

5.  Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.

Authors:  L Pekka Malmberg; Paula Rytilä; Pertti Happonen; Tari Haahtela
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

6.  Reduced Peak Inspiratory Effort through the Diskus((R)) and the Turbuhaler((R)) due to Mishandling is Common in Clinical Practice.

Authors:  Andrea S Melani; Letizia S Bracci; Marcello Rossi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

7.  Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD.

Authors:  Alexander G Duarte; Leon Tung; Wei Zhang; En Shuo Hsu; Yong-Fang Kuo; Gulshan Sharma
Journal:  Chronic Obstr Pulm Dis       Date:  2019-07-24

8.  Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.

Authors:  Wahida Azouz; Philip Chetcuti; Harold Hosker; Dinesh Saralaya; Henry Chrystyn
Journal:  BMC Pulm Med       Date:  2015-05-01       Impact factor: 3.317

9.  Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Authors:  David Prime; Wilfried de Backer; Melanie Hamilton; Anthony Cahn; Andrew Preece; Dennis Kelleher; Amanda Baines; Alison Moore; Noushin Brealey; Jackie Moynihan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-15       Impact factor: 2.849

10.  A review of the value of innovation in inhalers for COPD and asthma.

Authors:  Johann Christian Virchow; Cezmi A Akdis; Josep Darba; Richard Dekhuijzen; Sylvia Hartl; Gisela Kobelt; Albert Roger; Steven Simoens; Mondher Toumi; Ben Woodhouse; Adam Plich; Saku Torvinen
Journal:  J Mark Access Health Policy       Date:  2015-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.